LION bioscience Strengthens its Proteomics Expertise
HEIDELBERG, Germany and ODENSE, Denmark, Nov. 6 /PRNewswire/ -- LION bioscience AG (Neuer Markt: LIO, WKN 504 350, Nasdaq: LEON) and ACE BioSciences A/S today announced that they have entered into a collaboration agreement in the field of proteomics. LION has granted several user licenses for its software products to ACE BioSciences. ACE BioSciences will apply these modules to conduct its own proteomics research in the field of pathogenic microorganisms and deliver proprietary content for LION's piSCOUT(TM) software for the analysis of protein-protein interactions on an exclusive basis. As protein interactions are key for the understanding of molecular functions, analyzing these interactions will support the understanding of disease development and will be instrumental in the development of new drugs.
ACE BioSciences has gained access to LION's integration platform SRS, its software for the automated genome annotation bioSCOUT®, the analysis of protein-protein-interactions piSCOUT(TM) and genome comparison genomeSCOUT(TM). By comparing theoretical networks with experimental data ACE BioSciences will develop simulated protein interaction networks assisting the researcher in the prediction of interactions between different proteins. The information will be accessible solely via LION's piSCOUT(TM) module to industrial partners of ACE BioSciences and LION.
``With the integrated software solutions of LION we can most efficiently link theoretical information from comparative genomics with the scientific data of the ''real world`` experimental or functional proteomics results. This provides us with a competitive edge in the identification and development of novel drug targets,'' said Dr. Angus King, Chief Scientific Officer at ACE BioSciences.
``ACE BioSciences expertise in the field of functional proteomics makes them a key partner in this area for us,'' said Dr. Reinhard Schneider, Chief Information Officer of LION bioscience. ``The partnership with ACE BioSciences is a perfect example in exploiting LION's modular and integrated information management functionality for their research. Our collaboration with ACE BioSciences will strengthen our own expertise in the proteomics area.''
About LION bioscience AG:
LION bioscience (http://www.lionbioscience.com) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. These solutions integrate all R&D disciplines, spanning from genomics to early and late discovery through clinical trials. LION applies these solutions for its internal drug discovery program in the field of nuclear receptors with the goal to out-license specific databases, polymorphism marker panels, and validated targets and leads.
Founded in 1997, LION has more than 485 employees, with headquarters in Heidelberg, Germany, and subsidiaries in Cambridge, UK, Cambridge, MA, USA and San Diego, CA, USA. To date, LION has established partnerships with leading life science companies, including Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, GlaxoSmithKline, Janssen, Merck Inc., Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Roche, Sumitomo Pharmaceuticals and Tripos.
About ACE BioSciences A/S:
ACE BioSciences A/S (http://www.acebiosciences.com) is a biology driven biotech company with expertise in functional proteomics. We are building novel three-dimensional Protein Interaction Network databases (PINs) of pathogenic microorganisms. We collaborate with the pharmaceutical and biotechnology industries to use our PINs to identify markers and novel drug targets for human diseases caused by pathogenic microorganisms. ACE BioSciences has to date established alliances with Micromass, UK, IBM Lifesciences division, the Statens Serum Institute, Copenhagen and the University of Southern Denmark, Odense... |
